Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study

ConclusionsSerplulimab was well tolerated and demonstrated antitumor activity. These data support further study of serplulimab in larger patient populations.Clinical Trial RegistrationClinicalTrials.gov NCT03468751 (19 March, 2018).

Source: BioDrugs - January 9, 2024 Category: Drugs & Pharmacology Source Type: research